Skip to main content
. 2022 Mar 21;2(2):oeac019. doi: 10.1093/ehjopen/oeac019

Figure 6.

Figure 6

All-cause mortality in P2Y12 inhibitor monotherapy versus aspirin monotherapy. All-cause death was analyzed as a secondary outcome from the pooled analysis of 8 studies. Monotherapy with a P2Y12 inhibitor or aspirin had similar risks of all-cause death (RR 1.01 [95% CI 0.92–1.11], I2 = 0%). CI = confidence interval, P2Y12i = P2Y12 inhibitor, RR = risk ratio.